Lower risk of cardiovascular events in patients initiated on semaglutide 2.4 mg in the real-world: Results from the SCORE study (Semaglutide Effects on Cardiovascular Outcomes in People with Overweight or Obesity in the Real World).

Smolderen KG, Mena-Hurtado C, Zhao Z, Michalak W, Faurby M, Smolarz BG, Kosiborod MN, Song J, Chen Y, Boland J, Nanna MG

Diabetes, obesity & metabolism9 Sept 2025Cited by 9 (Europe PMC)

PMID40926360PMCIDPMC12515752DOI10.1111/dom.70080PepBankPUB-40926360

Read at source PubMedAsk about this study

Jump to 10 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study10

10 results from studies that gave the peptide. 10 results from people.

01HumanObservational studyEfficacy outcome
In adults with ASCVD and overweight/obesity without diabetes, semaglutide 2.4 mg was associated with a lower risk of rMACE-5 (HR 0.55).
In plain wordsIn adults with heart disease and overweight, starting semaglutide 2.4 mg was linked to fewer major heart events than not taking it.
Peptide
Semaglutide
Outcome
DecreaseRevised 5-point MACE (rMACE-5)
Study
n: not reported in source
Comparator
Not on semaglutide (matched)
Analysis
Primary
Outcome group
Cardiovascular events · Cardiovascular
Studied dose
2.4 mgAs given in this study (human).
Measurements
HR
0.55 ratio
rMACE-5
Source sentences
Summary
Over a mean follow-up of 200 days, semaglutide 2.4 mg was associated with significantly lower risks of rMACE-5 (hazard ratio: 0.55; p < 0.001), rMACE-3 (0.43; p < 0.001), MACE-5 (0.65; p < 0.001), and MACE-3 (0.58; p < 0.01).
1 context sentence(design, population, supporting numbers)
Summary · context
Individuals initiating semaglutide 2.4 mg aged ≥45 years with ASCVD and overweight/obesity but without diabetes were identified in a US database (01/01/2016-12/31/2023) and matched 1:2 to those not on semaglutide based on a non-parsimonious propensity-score model.
Report a problemFND-4092636001
02HumanObservational studyEfficacy outcome
In adults with ASCVD and overweight/obesity without diabetes, semaglutide 2.4 mg was associated with a lower risk of rMACE-3 (HR 0.43).
In plain wordsIn adults with heart disease and overweight, starting semaglutide 2.4 mg was linked to fewer heart attacks, strokes and deaths than not taking it.
Peptide
Semaglutide
Outcome
DecreaseRevised 3-point MACE (rMACE-3)
Study
n: not reported in source
Comparator
Not on semaglutide (matched)
Analysis
Primary
Outcome group
Cardiovascular events · Cardiovascular
Studied dose
2.4 mgAs given in this study (human).
Measurements
HR
0.43 ratio
rMACE-3
Source sentences
Summary
Over a mean follow-up of 200 days, semaglutide 2.4 mg was associated with significantly lower risks of rMACE-5 (hazard ratio: 0.55; p < 0.001), rMACE-3 (0.43; p < 0.001), MACE-5 (0.65; p < 0.001), and MACE-3 (0.58; p < 0.01).
1 context sentence(design, population, supporting numbers)
Summary · context
Individuals initiating semaglutide 2.4 mg aged ≥45 years with ASCVD and overweight/obesity but without diabetes were identified in a US database (01/01/2016-12/31/2023) and matched 1:2 to those not on semaglutide based on a non-parsimonious propensity-score model.
Report a problemFND-4092636002
03HumanObservational studyEfficacy outcome
In adults with ASCVD and overweight/obesity without diabetes, semaglutide 2.4 mg was associated with a lower risk of MACE-5 (HR 0.65).
In plain wordsIn adults with heart disease and overweight, starting semaglutide 2.4 mg was linked to fewer major heart events than not taking it.
Peptide
Semaglutide
Outcome
DecreaseMACE-5
Study
n: not reported in source
Comparator
Not on semaglutide (matched)
Analysis
Secondary
Outcome group
Cardiovascular events · Cardiovascular
Studied dose
2.4 mgAs given in this study (human).
Measurements
HR
0.65 ratio
MACE-5
Source sentences
Summary
Over a mean follow-up of 200 days, semaglutide 2.4 mg was associated with significantly lower risks of rMACE-5 (hazard ratio: 0.55; p < 0.001), rMACE-3 (0.43; p < 0.001), MACE-5 (0.65; p < 0.001), and MACE-3 (0.58; p < 0.01).
1 context sentence(design, population, supporting numbers)
Summary · context
Individuals initiating semaglutide 2.4 mg aged ≥45 years with ASCVD and overweight/obesity but without diabetes were identified in a US database (01/01/2016-12/31/2023) and matched 1:2 to those not on semaglutide based on a non-parsimonious propensity-score model.
Report a problemFND-4092636003
04HumanObservational studyEfficacy outcome
In adults with ASCVD and overweight/obesity without diabetes, semaglutide 2.4 mg was associated with a lower risk of MACE-3 (HR 0.58).
In plain wordsIn adults with heart disease and overweight, starting semaglutide 2.4 mg was linked to fewer major heart events than not taking it.
Peptide
Semaglutide
Outcome
DecreaseMACE-3
Study
n: not reported in source
Comparator
Not on semaglutide (matched)
Analysis
Secondary
Outcome group
Cardiovascular events · Cardiovascular
Studied dose
2.4 mgAs given in this study (human).
Measurements
HR
0.58 ratio
MACE-3
Source sentences
Summary
Over a mean follow-up of 200 days, semaglutide 2.4 mg was associated with significantly lower risks of rMACE-5 (hazard ratio: 0.55; p < 0.001), rMACE-3 (0.43; p < 0.001), MACE-5 (0.65; p < 0.001), and MACE-3 (0.58; p < 0.01).
1 context sentence(design, population, supporting numbers)
Summary · context
Individuals initiating semaglutide 2.4 mg aged ≥45 years with ASCVD and overweight/obesity but without diabetes were identified in a US database (01/01/2016-12/31/2023) and matched 1:2 to those not on semaglutide based on a non-parsimonious propensity-score model.
Report a problemFND-4092636004
05HumanObservational studyEfficacy outcome
In adults with ASCVD and overweight/obesity without diabetes, semaglutide 2.4 mg was associated with a lower risk of incident type 2 diabetes.
In plain wordsIn adults with heart disease and overweight, starting semaglutide 2.4 mg was linked to a lower risk of type 2 diabetes than not taking it.
Peptide
Semaglutide
Outcome
DecreaseIncident type 2 diabetes
Study
n: not reported in source
Comparator
Not on semaglutide (matched)
Analysis
Exploratory
Outcome group
Glycemic control · Metabolic and weight
Studied dose
2.4 mgAs given in this study (human).
Source sentences
Summary
Semaglutide 2.4 mg was also associated with lower risks of all-cause mortality, cardiovascular-related mortality, hospitalisation for heart failure, and all exploratory outcomes.
2 context sentences(design, population, supporting numbers)
Summary · context
Exploratory outcomes included incident type 2 diabetes, major adverse kidney events, and major obesity-related adverse events.
Summary · context
Individuals initiating semaglutide 2.4 mg aged ≥45 years with ASCVD and overweight/obesity but without diabetes were identified in a US database (01/01/2016-12/31/2023) and matched 1:2 to those not on semaglutide based on a non-parsimonious propensity-score model.
Report a problemFND-4092636008
06HumanObservational studyEfficacy outcome
In adults with ASCVD and overweight/obesity without diabetes, semaglutide 2.4 mg was associated with a lower risk of major adverse kidney events.
In plain wordsIn adults with heart disease and overweight, starting semaglutide 2.4 mg was linked to fewer major kidney problems than not taking it.
Peptide
Semaglutide
Outcome
DecreaseMajor adverse kidney events
Study
n: not reported in source
Comparator
Not on semaglutide (matched)
Analysis
Exploratory
Outcome group
Kidney function · Kidney and urinary
Studied dose
2.4 mgAs given in this study (human).
Source sentences
Summary
Semaglutide 2.4 mg was also associated with lower risks of all-cause mortality, cardiovascular-related mortality, hospitalisation for heart failure, and all exploratory outcomes.
2 context sentences(design, population, supporting numbers)
Summary · context
Exploratory outcomes included incident type 2 diabetes, major adverse kidney events, and major obesity-related adverse events.
Summary · context
Individuals initiating semaglutide 2.4 mg aged ≥45 years with ASCVD and overweight/obesity but without diabetes were identified in a US database (01/01/2016-12/31/2023) and matched 1:2 to those not on semaglutide based on a non-parsimonious propensity-score model.
Report a problemFND-4092636009
07HumanObservational studyEfficacy outcome
In adults with ASCVD and overweight/obesity without diabetes, semaglutide 2.4 mg was associated with a lower risk of major obesity-related adverse events.
In plain wordsIn adults with heart disease and overweight, starting semaglutide 2.4 mg was linked to fewer major obesity-related health problems than not taking it.
Peptide
Semaglutide
Outcome
DecreaseMajor obesity-related adverse events
Study
n: not reported in source
Comparator
Not on semaglutide (matched)
Analysis
Exploratory
Outcome group
Adverse events · Metabolic and weight
Studied dose
2.4 mgAs given in this study (human).
Source sentences
Summary
Semaglutide 2.4 mg was also associated with lower risks of all-cause mortality, cardiovascular-related mortality, hospitalisation for heart failure, and all exploratory outcomes.
2 context sentences(design, population, supporting numbers)
Summary · context
Exploratory outcomes included incident type 2 diabetes, major adverse kidney events, and major obesity-related adverse events.
Summary · context
Individuals initiating semaglutide 2.4 mg aged ≥45 years with ASCVD and overweight/obesity but without diabetes were identified in a US database (01/01/2016-12/31/2023) and matched 1:2 to those not on semaglutide based on a non-parsimonious propensity-score model.
Report a problemFND-4092636010
08HumanObservational studyEfficacy outcome
In adults with ASCVD and overweight/obesity without diabetes, semaglutide 2.4 mg was associated with a lower risk of all-cause mortality.
In plain wordsIn adults with heart disease and overweight, starting semaglutide 2.4 mg was linked to a lower risk of death than not taking it.
Peptide
Semaglutide
Outcome
DecreaseAll-cause mortality
Study
n: not reported in source
Comparator
Not on semaglutide (matched)
Outcome group
Mortality · Cardiovascular
Studied dose
2.4 mgAs given in this study (human).
Source sentences
Summary
Semaglutide 2.4 mg was also associated with lower risks of all-cause mortality, cardiovascular-related mortality, hospitalisation for heart failure, and all exploratory outcomes.
1 context sentence(design, population, supporting numbers)
Summary · context
Individuals initiating semaglutide 2.4 mg aged ≥45 years with ASCVD and overweight/obesity but without diabetes were identified in a US database (01/01/2016-12/31/2023) and matched 1:2 to those not on semaglutide based on a non-parsimonious propensity-score model.
Report a problemFND-4092636005
09HumanObservational studyEfficacy outcome
In adults with ASCVD and overweight/obesity without diabetes, semaglutide 2.4 mg was associated with a lower risk of cardiovascular-related mortality.
In plain wordsIn adults with heart disease and overweight, starting semaglutide 2.4 mg was linked to a lower risk of heart-related death than not taking it.
Peptide
Semaglutide
Outcome
DecreaseCardiovascular-related mortality
Study
n: not reported in source
Comparator
Not on semaglutide (matched)
Outcome group
Mortality · Cardiovascular
Studied dose
2.4 mgAs given in this study (human).
Source sentences
Summary
Semaglutide 2.4 mg was also associated with lower risks of all-cause mortality, cardiovascular-related mortality, hospitalisation for heart failure, and all exploratory outcomes.
1 context sentence(design, population, supporting numbers)
Summary · context
Individuals initiating semaglutide 2.4 mg aged ≥45 years with ASCVD and overweight/obesity but without diabetes were identified in a US database (01/01/2016-12/31/2023) and matched 1:2 to those not on semaglutide based on a non-parsimonious propensity-score model.
Report a problemFND-4092636006
10HumanObservational studyEfficacy outcome
In adults with ASCVD and overweight/obesity without diabetes, semaglutide 2.4 mg was associated with a lower risk of hospitalisation for heart failure.
In plain wordsIn adults with heart disease and overweight, starting semaglutide 2.4 mg was linked to fewer heart failure hospital stays than not taking it.
Peptide
Semaglutide
Outcome
DecreaseHospitalisation for heart failure
Study
n: not reported in source
Comparator
Not on semaglutide (matched)
Outcome group
Cardiovascular events · Cardiovascular
Studied dose
2.4 mgAs given in this study (human).
Source sentences
Summary
Semaglutide 2.4 mg was also associated with lower risks of all-cause mortality, cardiovascular-related mortality, hospitalisation for heart failure, and all exploratory outcomes.
1 context sentence(design, population, supporting numbers)
Summary · context
Individuals initiating semaglutide 2.4 mg aged ≥45 years with ASCVD and overweight/obesity but without diabetes were identified in a US database (01/01/2016-12/31/2023) and matched 1:2 to those not on semaglutide based on a non-parsimonious propensity-score model.
Report a problemFND-4092636007

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase not statedNCT06874751

Semaglutide Effects on Cardiovascular Outcomes in People With Overweight or Obesity in the Real World

Novo Nordisk A/Sn = 45,4566 Dec 2024 to 28 Mar 2025

Overweight · Obesity · Atherosclerotic Cardiovascular Disease (ASCVD)

Trial page ClinicalTrials.govUpdated 21 May 2025

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
11 Oct 2026, 00:04 UTC
Study results updated
Version 1
9 Oct 2026, 03:06 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.